Does matrix metalloproteinase-3 polymorphism play a role in age-related macular degeneration in patients with myocardial infarction?

• Published in: Medicina (Kaunas, Lithuania) Vol. 48; no. 8; pp. 404 - 409
• Main Authors: Liutkevičienė, Rasa, Žaliaduonytė-Pekšienė, Diana, Žaliūnienė, Dalia, Gustienė, Olivija, Jašinskas, Vytautas, Lesauskaitė, Vaiva, Tamošiūnas, Abdonas, Žaliūnas, Remigijus
• Format: Journal Article
• Language: English
• Published: Switzerland 01-01-2012
• Subjects: Aged; Female; Humans; Lithuania - epidemiology; Macular Degeneration - epidemiology; Macular Degeneration - genetics; Male; Matrix Metalloproteinase 3 - genetics; Middle Aged; Myocardial Infarction - epidemiology; Polymorphism, Genetic; Lithuania
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina48080060

The aim of our study was to determine if the genotype of the matrix metalloproteinase-3 (MMP-3) gene might carry the risk of age-related macular degeneration (ARMD) in patients with myocardial infarction.
A total of 499 patients with an acute myocardial infarction or with a history of myocardial infarction were enrolled into the study. They were subdivided into 2 groups: 273 patients with ARMD and 226 patients without ARMD. The control group comprised 560 persons from a random sample of the Lithuanian population. DNA was analyzed using real-time polymerase chain reaction to genotype polymorphism 5A/6A at a position -1171 of the MMP-3 gene promoter.
Of the 499 patients with myocardial infarction, 47% had early-stage ARMD. The patients with ARMD were older than the patients in the group without ARMD (62.1±10.8 vs. 59.6±11.1, P<0.01). The analysis of MMP-3 gene polymorphism did not reveal any differences in the distribution of 5A/5A, 5A/6A, and 6A/6A genotypes between the ARMD group, non-ARMD group, and the control group (24.2%, 52.5%, and 23.3% in the ARMD group; 28.7%, 51.9%, and 19.4% in non-ARMD group; and 25.7%, 49.3% and 25.0%, in the control group, respectively).
MMP-3 gene polymorphism had no predominant effect on the development of ARMD in patients with myocardial infarction.